Nothing Special   »   [go: up one dir, main page]

PT1687019T - Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção - Google Patents

Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção

Info

Publication number
PT1687019T
PT1687019T PT47974530T PT04797453T PT1687019T PT 1687019 T PT1687019 T PT 1687019T PT 47974530 T PT47974530 T PT 47974530T PT 04797453 T PT04797453 T PT 04797453T PT 1687019 T PT1687019 T PT 1687019T
Authority
PT
Portugal
Prior art keywords
optimal
production
propylene glycol
injection devices
containing peptide
Prior art date
Application number
PT47974530T
Other languages
English (en)
Inventor
Bjeldskov Pedersen Tina
Bonde Claude
Kot Engelund Dorthe
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34609967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1687019(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PT1687019T publication Critical patent/PT1687019T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT47974530T 2003-11-20 2004-11-18 Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção PT1687019T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200301719 2003-11-20

Publications (1)

Publication Number Publication Date
PT1687019T true PT1687019T (pt) 2018-02-26

Family

ID=34609967

Family Applications (2)

Application Number Title Priority Date Filing Date
PT17196501T PT3300721T (pt) 2003-11-20 2004-11-18 Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção
PT47974530T PT1687019T (pt) 2003-11-20 2004-11-18 Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT17196501T PT3300721T (pt) 2003-11-20 2004-11-18 Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção

Country Status (20)

Country Link
US (5) US8114833B2 (pt)
EP (3) EP2394656B1 (pt)
JP (2) JP5558655B2 (pt)
KR (1) KR101243648B1 (pt)
CN (4) CN113304250A (pt)
AU (1) AU2004290862B2 (pt)
BR (1) BRPI0416743A (pt)
CA (1) CA2545034C (pt)
CY (1) CY1119723T1 (pt)
DK (2) DK1687019T3 (pt)
ES (2) ES2727854T3 (pt)
HK (1) HK1246683B (pt)
HU (2) HUE043210T2 (pt)
MX (1) MXPA06005581A (pt)
PL (2) PL1687019T3 (pt)
PT (2) PT3300721T (pt)
RU (1) RU2421238C2 (pt)
SI (2) SI3300721T1 (pt)
TR (1) TR201906789T4 (pt)
WO (1) WO2005049061A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1412384E (pt) * 2001-06-28 2008-03-28 Novo Nordisk As Formulação estável de glp-1 modificado
SI3300721T1 (sl) 2003-11-20 2019-07-31 Novo Nordisk A/S Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
EP2502618A3 (en) 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2011504871A (ja) * 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
RU2472492C2 (ru) * 2007-06-01 2013-01-20 Ново Нордиск А/С Стабильные неводные фармацевтические композиции
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8031419B2 (en) 2009-07-28 2011-10-04 Hong Kong Applied Science and Technology Research Institute, Co., Ltd. Compact imaging device
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
AU2011227083B2 (en) * 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
EP3730127A1 (en) 2010-12-16 2020-10-28 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
MX2014001190A (es) * 2011-08-10 2014-05-12 Adocia Solucion inyectable de al menos insulina basal.
SI2827885T1 (sl) 2012-03-22 2018-10-30 Novo Nordisk A/S Sestavki peptidov GLP-1 in njihova priprava
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
BR112014032938A2 (pt) 2012-07-01 2017-08-01 Novo Nordisk As uso de peptídeos de glp-1 de longa ação
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
CN104415326A (zh) * 2013-08-28 2015-03-18 深圳翰宇药业股份有限公司 一种含有利拉鲁肽的药物制剂组合物及其制备方法
EP3055325B1 (en) 2013-10-07 2018-01-03 Novo Nordisk A/S Novel derivative of an insulin analogue
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
EP3295952B1 (en) * 2015-05-13 2021-02-17 Hangzhou Jiuyuan Gene Engineering Co., Ltd Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
AU2016267052B2 (en) 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3424521A4 (en) * 2016-03-01 2019-12-18 Hybio Pharmaceutical Co., Ltd PHARMACEUTICAL COMPOSITION AND PRODUCTION METHOD THEREFOR
US9968659B2 (en) * 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017149105A1 (en) * 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in renal conditions
MY189551A (en) * 2016-06-20 2022-02-16 Isa Pharmaceuticals B V Formulation of a peptide vaccine
US10350293B2 (en) 2016-08-23 2019-07-16 Pharmacotherapia d.o.o. Compositions and methods for treating symptoms associated with multiple sclerosis
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
EP3541366A4 (en) 2016-11-21 2020-08-05 Eiger Biopharmaceuticals, Inc. BUFFERED FORMULATIONS FROM EXENDIN (9-39)
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
CN111212657A (zh) 2017-10-12 2020-05-29 诺沃挪第克公司 用于药物治疗的司美鲁肽
CN118873634A (zh) 2018-02-02 2024-11-01 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
EP3863607A4 (en) * 2018-10-09 2022-07-06 Dat Tran COMPOSITIONS AND METHODS TO ENHANCE THE SYSTEMIC DELIVERY, TOLERANCE AND EFFICACY OF CATIONIC MACROCYCLIC PEPTIDES
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
US11471512B2 (en) 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
WO2020208541A1 (en) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20240216476A1 (en) 2021-04-27 2024-07-04 Aardvark Therapeutics, Inc. Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8148073A0 (it) 1980-03-21 1981-03-20 Wellcome Found Formulazione oftalmica a base di trimethoprim e di polymyxin contenente un agente stabilizzante a base di mercurio
US4483849A (en) 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
EP0305387B2 (en) 1986-05-05 1996-08-28 The General Hospital Corporation Insulinotropic hormone
WO1988008673A1 (en) 1987-05-14 1988-11-17 Commonwealth Scientific And Industrial Research Or Whey protein fractions
JPH03505401A (ja) 1988-06-27 1991-11-28 ジェネックス・コーポレーション 組換えタンパク質の培養培地への熱放出
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
JP2822447B2 (ja) * 1989-05-19 1998-11-11 住友電気工業株式会社 酸化物超電導線材の製造方法および装置
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE69013471T2 (de) 1989-12-05 1995-03-30 Merck & Co Inc Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DK0512042T3 (da) 1990-01-24 1998-05-11 Douglas I Buckley GLP-1-analoger anvendelige ved diabetesbehandling
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
EP0482608B1 (en) * 1990-10-26 1994-07-27 The Furukawa Electric Co., Ltd. A polyphenylenesulfide composition for powder coating
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) * 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995000550A1 (en) 1993-06-21 1995-01-05 Novo Nordisk A/S Aspb28 insulin crystals
AU7531094A (en) * 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
PT792290E (pt) 1993-09-17 2002-01-30 Novo Nordisk As Insulina acilada
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
DE69422637T2 (de) * 1993-11-19 2000-06-08 G.D. Searle & Co., Chicago Transdermale zusammensetzung von n-(n-(5-(4-(aminoiminomethyl)phenyl-1-oxopentyl)-l-alpha-aspartyl)-l-phenylalanin oder deren esterderivaten und ihre pharmazeutischverwendbaren salze
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en) * 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
EP0699687B1 (en) 1994-08-31 2004-01-28 Mitsubishi Pharma Corporation Process for purifying recombinant human serum albumin
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
EP0820299B1 (en) 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
EP0828753B1 (en) 1995-06-02 2003-03-26 Novozymes A/S Al/Fe-TREATMENT OF A PROTEIN SOLUTION, FOLLOWED BY MEMBRANE CONCENTRATION
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
CA2257119A1 (en) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin analogues, processes for their production and pharmaceutical preparations containing them
RO119862B1 (ro) * 1996-07-03 2005-05-30 Alza Corporation Formulare stabilă neapoasă şi procedeu pentru prepararea acesteia
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6274553B1 (en) 1997-01-20 2001-08-14 Japan Energy Corporation Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method
AU6586298A (en) 1997-03-31 1998-10-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EP1029536B1 (en) * 1997-10-01 2007-11-28 Novadel Pharma Inc. Buccal non-polar spray
EP1025126B1 (en) 1997-10-24 2003-04-16 Genentech, Inc. Purification of molecules
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
WO2000015224A1 (en) 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
DE69928006T2 (de) * 1998-12-22 2006-07-13 Eli Lilly And Co., Indianapolis Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
ES2315226T3 (es) 1999-03-17 2009-04-01 Novo Nordisk A/S Metodo de acilacion de peptidos y proteinas.
JP2003503356A (ja) 1999-06-25 2003-01-28 メドトロニック ミニメド インコーポレイテッド 多剤糖尿病治療
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU7363000A (en) 1999-09-20 2001-04-24 Eli Lilly And Company Method for reducing the risk of cancer
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1242121B1 (en) 1999-12-16 2005-02-09 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US20010012829A1 (en) * 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
BR0107837A (pt) 2000-01-27 2003-01-14 Lilly Co Eli Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
DK1695983T3 (da) 2000-06-16 2009-05-18 Lilly Co Eli Glucagon-lignende peptid-1 analoger
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
SI1355942T1 (sl) 2000-12-07 2009-02-28 Lilly Co Eli Glp-1 fuzijski proteini
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
EP1360202B1 (en) 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
WO2002074978A2 (en) * 2001-03-19 2002-09-26 President And Fellows Of Harvard College Nucleic acid shuffling
WO2002098445A1 (en) 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Protein preparation
PT1412384E (pt) 2001-06-28 2008-03-28 Novo Nordisk As Formulação estável de glp-1 modificado
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
NZ531788A (en) 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005508360A (ja) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
WO2003077937A1 (en) 2002-03-15 2003-09-25 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
EP1494704A1 (en) 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
WO2004029076A2 (en) 2002-09-25 2004-04-08 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
AU2004243531B2 (en) 2003-06-03 2009-11-05 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1684793B1 (en) * 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
SI3300721T1 (sl) 2003-11-20 2019-07-31 Novo Nordisk A/S Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1814581B1 (en) * 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
BR112013019734A2 (pt) * 2011-02-04 2016-10-25 Biocopea Ltd composições e métodos para tratar inflamação crônica e doenças inflamatórias
CN102579350B (zh) * 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂

Also Published As

Publication number Publication date
SI1687019T1 (en) 2018-04-30
EP2394656A2 (en) 2011-12-14
WO2005049061A3 (en) 2005-10-20
CN113304250A (zh) 2021-08-27
WO2005049061A8 (en) 2005-12-01
ES2660320T3 (es) 2018-03-21
PL3300721T3 (pl) 2019-08-30
TR201906789T4 (tr) 2019-05-21
EP1687019B1 (en) 2017-11-22
CN102784386A (zh) 2012-11-21
PL1687019T3 (pl) 2018-05-30
WO2005049061A2 (en) 2005-06-02
CN104826116A (zh) 2015-08-12
EP3300721A1 (en) 2018-04-04
RU2006116414A (ru) 2007-12-27
HK1246683B (zh) 2019-11-15
CN1882356B (zh) 2015-02-25
CN1882356A (zh) 2006-12-20
KR101243648B1 (ko) 2013-03-14
PT3300721T (pt) 2019-06-06
ES2727854T3 (es) 2019-10-21
SI3300721T1 (sl) 2019-07-31
US20120225810A1 (en) 2012-09-06
EP1687019A2 (en) 2006-08-09
MXPA06005581A (es) 2006-08-11
US20190231876A1 (en) 2019-08-01
US20070010424A1 (en) 2007-01-11
JP2007513084A (ja) 2007-05-24
US20230364241A1 (en) 2023-11-16
EP2394656B1 (en) 2023-12-13
US20200316204A1 (en) 2020-10-08
DK1687019T3 (en) 2018-02-12
CA2545034C (en) 2013-03-05
JP5670373B2 (ja) 2015-02-18
JP5558655B2 (ja) 2014-07-23
AU2004290862A1 (en) 2005-06-02
AU2004290862B2 (en) 2010-06-03
RU2421238C2 (ru) 2011-06-20
CY1119723T1 (el) 2018-06-27
HUE043210T2 (hu) 2019-08-28
KR20060100428A (ko) 2006-09-20
BRPI0416743A (pt) 2007-01-16
CA2545034A1 (en) 2005-06-02
EP2394656A3 (en) 2012-01-18
HUE038395T2 (hu) 2018-10-29
JP2012188424A (ja) 2012-10-04
US8114833B2 (en) 2012-02-14
DK3300721T3 (da) 2019-05-27
EP3300721B1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
HK1246683B (zh) 對於生產和用於注射裝置中是最佳的含有丙二醇的肽製劑
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
IL162642A0 (en) Formulations
IL164519A0 (en) Pharmaceutical formulations
IL174131A0 (en) Improvements in vaccination
IL172824A0 (en) Pharmaceutical formulations
GB0206461D0 (en) Improvements in vaccination
AU2003239248A8 (en) Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
GB0323701D0 (en) Formulations
GB2392093B (en) Pharmaceutical formulations
GB0324265D0 (en) Peptide
AU2003228863A8 (en) Immunogenic peptides
IL174308A0 (en) Therapeutic formulations
GB0307765D0 (en) Tissue-adhesive formulations
EP1549291A4 (en) INJECTION FORMULATION
HK1134030A1 (en) Survivin-derived peptides and use thereof
GB0317376D0 (en) Immunogenic protein and uses thereof
GB0311936D0 (en) Improvements in devices
EP1699809A4 (en) PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0213005D0 (en) Injection nozzle
TW563410U (en) Combining plastic blocks used in gardens
EP1551330A4 (en) IMPROVEMENTS IN THE TECHNOLOGY OF THE CONTRIBUTION
GB0315664D0 (en) Nozzle arrangements
TW580950U (en) Improved nozzle head structure for use in horticulture
GB0207232D0 (en) Improvements in pharmaceutical compositions